Hepatitis B Topics HBV Treatment
DDW 2013: Does HBV Suppression Prevent Liver Disease Progression?
- Details
- Category: HBV Treatment
- Published on Wednesday, 19 June 2013 00:00
- Written by Liz Highleyman
Chronic hepatitis B patients with cirrhosis may still experience liver disease progression even if they undergo antiviral treatment and achieve good virological response, according to a poster presented at the Digestive Disease Week meeting (DDW 2013) last month in Orlando.
DDW 2013: Tenofovir and Entecavir Effectively Suppress Hepatitis B Virus
- Details
- Category: HBV Treatment
- Published on Thursday, 06 June 2013 00:00
- Written by Liz Highleyman
The newer antivirals tenofovir (Viread) and entecavir (Baraclude) inhibit hepatitis B virus (HBV) replication more effectively than older agents, but good adherence is needed to maintain long-term viral suppression, according to a set of studies presented at the Digestive Disease Week meeting (DDW 2013) last month in Orlando.
EASL 2013: Do Asian Patients Respond Better to Pegylated Interferon for Hepatitis B?
- Details
- Category: HBV Treatment
- Published on Wednesday, 08 May 2013 00:00
- Written by Liz Highleyman
Some Asian people with chronic hepatitis B treated with pegylated interferon may experience better outcomes on certain measures than Caucasians, though overall response rates are similar, according to a comparative analysis presented at the EASL International Liver Congress(EASL 2013) last month in Amsterdam. The study also showed that early hepatitis B surface antigen (HBsAg) decline is a predictor of treatment response in some patients.
Coverage of Digestive Disease Week 2013
- Details
- Category: HBV Treatment
- Published on Wednesday, 22 May 2013 00:00
- Written by Liz Highleyman
HIVandHepatitis.com coverage of the 2013 Digestive Disease Week annual meeting (DDW 2013) in Orlando, Florida, May 18-21, 2013.
Conference highlights include direct-acting hepatitis C drugs, new strategies for using approved HCV protease inhibitors and interferon/ribavirin, and interferon-free regimens.
HIVandHepatitis.com DDW 2013 conference section
5/22/13
EASL 2013: Truvada Works Best for Immune-Tolerant Hepatitis B Patients -- But Do They Need Treatment?
- Details
- Category: HBV Treatment
- Published on Monday, 29 April 2013 00:00
- Written by Liz Highleyman
A combination of tenofovir and emtricitabine (the drugs in Truvada) suppressed hepatitis B virus (HBV) replication more than tenofovir alone over 4 years for people with inactive or immune-tolerant disease, researchers reported at the EASL International Liver Congress (EASL 2013) this week in Amsterdam. The benefits of treatment at this early stage, however, remain uncertain.
More Articles...
- Coverage of the 2013 EASL International Liver Congress
- EASL 2013: Long-term Tenofovir Reduces Liver Cancer Risk in People with Chronic Hepatitis B
- EASL 2013: International Liver Congress Kicks Off with Hep C New Drug Highlights
- Heavy Alcohol Use Increases Liver Cancer Risk in Hepatitis B Patients with Cirrhosis
Web Design and Development by